Curis Faces Nasdaq Delisting After Failing to Meet Minimum Bid Price
summarizeSummary
Curis Inc. has received a delisting notice from Nasdaq, effective May 6, 2026, after its common stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days. This critical development follows the company's recent 10-K filing, which revealed substantial doubt about its ability to continue as a going concern, and a proposal to significantly increase authorized common stock, indicating ongoing financial challenges. The delisting notice is a severe blow, as it will significantly impair the stock's liquidity and investor confidence, potentially forcing it to trade on an over-the-counter market. Curis intends to appeal the decision by May 4, 2026, but there is no guarantee of success. Traders should closely monitor the outcome of the appeal process and any subsequent announcements regarding the company's listing status.
At the time of this announcement, CRIS was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.7M. The 52-week trading range was $0.49 to $3.13. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.